MILDRONATE POTENTIAL FOR CORRECTING COGNITIVE DYSFUNCTION IN ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION

The study aimed to assess the effects of long-term and course mildronate therapy (500 mg/d) on cognitive function in elderly patients with arterial hypertension (AH) and cognitive dysfunction. This open, randomised, controlled comparative study in parallel groups (long-term therapy for 52 weeks, or two three-month courses over a year vs. standard therapy for 52 weeks) included 180 elderly patients with AH and cognitive dysfunction. Neuro-psychological examination included MMSE test, Reitan test, Wechsler test, test for speech activity, memory (10 words), and serial count, kinetic test, and MFI-20 test for asthenia assessment. Depression and anxiety symptoms were assessed with Beck and Tailor scales, respectively. Long-term mildronate therapy was the only treatment regimen improving all cognitive function parameters, compared to baseline and the control group. In the course mildronate therapy group, some cognitive function parameters did not change significantly, compared to baseline; however, the final values were not significantly different from those in the long-term mildronate therapy group. Course therapy was more effective than standard treatment in terms of improving the asthenia and anxiety scale parameters.

1. Frisoni G.B., Galluzzi S., Bresciani L. et al. Mild cognitive impairment with subcortical vascular features. Clinical characteristics and outcome // J. Neurol 2002; Vol. 249: P. 1423–1432

2. Lehrl S., Gr ssel E, Eicke C. Effectiveness of felodipine in hypertensive patients with mild cerebral cognition disorders in a randomized double-blind study// Deutsche medizinische Wochenschrift 2000; Vol. 125: P. 1350-5

3. Meyer J.S., Xu G., Thornby J. et al. Is mild cognitive impairment prodromal for vascular dementia like Alzheimer’s disease? // Stroke 2002; Vol. 33: P. 1981–85.

4. Murray M.D., Lane K.A., Gao S. et al. Preservation of cognitive function with antihypertensive medication: a longitudinal analysis of community-based sample of African Americans. Arch Intern Med 2002; 162: 2090-6.

5. Skoog I. A Longitudinal Population Study of the Mini-Mental State Examination in the Very Old: Relation to Dementia and Education // Dementia and Geriatric Cognitive Disorders 2000; Vol. 11: P431-37

6. Янсен В., Брукнер Г. Лечение хронической церебральной недостаточности с использованием драже Актовегин форте (двойное слепое плацебо-контролируемое исследование) // Русский медицинский журнал 2002; том 10: С 543-546

7. Яхно Н.Н., Дамулин И.В., Захаров В.В и др. Применение Танакана при начальных стадиях сосудистой мозговой недостаточности: результаты открытого мультицентрового исследования// Неврол.журнал 1998; Т.З: С.18–22.

8. Недогода С.В., Цома В.В., Ледяева А.А. и др. Актовегин в коррекции когнитивных нарушений у лиц старческого возраста с артериальной гипертензией // Атмосфера. Нервные болезни. 2009; 1: с.20-24.